The FDA-approved device tackles venous obstructions with a dual-stent design that includes hybrid and extend stents, according to a June 18 system news release shared with Becker’s. The study that led to its FDA approval enrolled 162 subjects across 30 centers, including Sanger. It found after 12 months, 90.2% of treated veins remained open and unobstructed and that the system had a success rate of 98.7%.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
